Publications & Reports

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

Thomas Mikeska, Kathryn Alsop, Gillian Mitchell, David Dl Bowtell, Alexander Dobrovic
Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. [email protected]

Abstract

BACKGROUND: High-grade serous ovarian cancers are a distinct histological subtype of ovarian cancer often characterised by a dysfunctional BRCA/Fanconi anaemia (BRCA/FA) pathway, which is critical to the homologous recombination DNA repair machinery. An impaired BRCA/FA pathway sensitises tumours to the treatment with DNA cross-linking agents and to PARP inhibitors. The vast majority of inactivating mutations in the BRCA/FA pathway are in the BRCA1 and BRCA2 genes and occur predominantly in high-grade serous cancer. Another member of the BRCA/FA pathway, PALB2 (FANCN), was reported to have been inactivated by DNA methylation in some sporadic ovarian cancers. We therefore sought to investigate the role of PALB2 methylation in high-grade serous ovarian cancers. FINDING: PALB2 methylation was investigated in 92 high-grade serous ovarian cancer samples using methylation-sensitive high-resolution melting analysis. DNA methylation of PALB2 was not detected in any of the ovarian cancer samples investigated. CONCLUSION: Epigenetic silencing by DNA methylation of PALB2 is not a common event in high-grade serous ovarian cancers.

Publication

  • Journal: Journal of Ovarian Research
  • Published: 12/04/2013
  • Volume: 6
  • Issue: 1
  • Pagination: 26

Author